Entering text into the input field will update the search result below

It Is Finally Time To Get Into Adamis Pharmaceuticals

Hot biotech stocks profile picture
Hot biotech stocks


  • Adamis is one of the winners of the firestorm surrounding unjustified price hikes of Mylan's EpiPen since it provides a lower cost alternative.
  • Company’s recent update brings the hope back that there is really a co-promotion deal being worked out for Symjepi’s launch.
  • U.S. application seeking approval to expand the indicated population to include pediatric patients weighing 33-65 pounds has been submitted.
  • Even with competition and competitor drugs, Adamis' current market capitalization is too low considering the opportunity it provides.
  • If Adamis can gain 5-10% of the 1.1 billion EpiPen market, it will be a major boost for its share price.

This video summarizes this article and provide a strategy for how to trade the stock.


This is how the company describes itself in its website,

"Adamis Pharmaceuticals Corporation is a specialty biopharmaceutical company focused on developing and commercializing products in the therapeutic areas of respiratory disease and allergy. The Company has an FDA approved product, Symjepi, which is an Epinephrine Injection pre-filled syringe product for use in the emergency treatment of anaphylaxis."

Adamis (NASDAQ:ADMP) uses already approved products and compounds, reformulates them, or makes generic versions of them, which it them to utilize 505(B)(2) regulatory route which permits it to skip the pre-clinical and Phase 1 clinical study phase of the drug development. This makes the path to market much shorter and cheaper. It uses new platform Taper Dry Powder Inhaler (DPI) technology that it acquired from 3M (MMM).

The Journey After Symjepi's Approval

It has been a very painful ride for the ADMP stockholders. Its NDA for a SymjepiTM, which is a generic version of EpiPen, was approved in June of last year. The company had announced that it would look for a co-promotion with a big player and had no intention to launch the product by itself. The wait for the announcement of its co-promotion deal has been long and frustrating. The delay caused a major drop in the stock price until the recent update from the company. The company just announced that it is working with two potential companies, and the next press release will be about the final deal. Let's hope this happens soon and does not take another eight months.

I thought the co-promoters were waiting for Adamis' supplement NDA which will expand the population to include pediatric patients weighing 33-65 pounds to get approved before signing a deal, but it seems like that's not the

This article was written by

Hot biotech stocks profile picture
The opinions are mine and are not intended to be used as a personalized investment recommendation. Please note I am NOT a certified financial adviser.”

Analyst’s Disclosure: I am/we are long ADMP. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.